Abstract 233P
Background
Host inflammation status, as reflected by serum markers such as c-reactive protein, has been reported to be of prognostic significance. peripheral blood Interferon Stimulated Gene 15 (ISG15) messenger ribonucleic acid (mRNA) expression is a novel circulating marker for type-I interferon response for inflammation In this report, we assessed the correlation between ISG15 gene expression and clinical factors, and the prognostic significance of ISG15 in patients with liver cancer.
Methods
Demographic, clinical, laboratory data were collected at study entrance from newly diagnosed liver cancer patients. ISG15 mRNA levels from peripheral blood mononuclear cells and granulocytes were measured. Receiver operating characteristic (ROC) curve of ISG15 mRNA level was plotted for leucocytosis to determine an optimal cut-off for high ISG15 gene expression. Blood was tested for cell counts, renal and liver functions, clotting profile, AFP, hepatitis B surface antigen and anti-hepatitis C antibodies. Patients were followed-up until death to capture survival data. Prognostic significance of clinical factors for OS were identified using Cox regressions. Significant non-overlapping clinical factors were analysed in multivariate Cox regression models to identify independent prognostic factors.
Results
The mean peripheral blood ISG15 mRNA level was 2.82 (standard deviation [SD] 5.38) FC. There was no significant correlation between ISG15 gene expression and clinical factors including age, sex, bloods counts, viral status, alkaline phosphatase and alanine transaminase, clotting profile, serum creatinine and presence of hepatic metastasis. Patients with high ISG15 gene expression had significantly shorter median OS than those with low expression, 4.7 versus 14.3 months respectively (p<0.03).
Conclusions
This is the first study to report peripheral blood ISG15 gene expression as an independent prognostic factor for OS in HCC patients. There was no significant correlation between ISG15 gene expression and clinical factors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.